Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 1;65(7):1151–1164. doi: 10.1136/gutjnl-2014-308270

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Treatment with 5-aminosalicylic acid (5-ASA) decreases B-cell CLL/lymphoma 3 (BCL-3) expression in colorectal cancer cells. Low BCL-3 expressing SW480 (A) and high BCL-3 expressing HCT116 (B) and HCA7 (C) cells were seeded for 48 h prior to treatment with 20 mM 5-ASA. Data was assessed at 24, 48 and 72 h post treatment. Western analysis showed expression of BCL-3 was decreased in all cells at 24, 48 and 72 h. Quantification of BCL-3 by densitometry normalised to its control is shown. (D) The high endogenous BCL-3 expressing cells (HCT116 and HCA7) were seeded for 48 h prior to treatment with 0, 10 or 20 mM 5-ASA. Western analysis shows BCL-3 expression was suppressed with 10 and 20 mM 5-ASA 48 h post treatment.